ATAC - Endometrial Sub-Protocol

AstraZeneca285 enrolled

Overview

To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

285

Conditions

Breast Cancer

Interventions

Anastrozole (Arimidex)DRUG

1mg, orally, once daily

Tamoxifen (Nolvadex)DRUG

20mg, orally, once daily

Nolvadex placeboDRUG

Arimidex placebo

Eligibility

Sex: FEMALEMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients eligible for entry into the main ATAC trial (1033IL/0029) * Not received any previous tamoxifen, for whatever reason * Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years * No previous endometrial ablation Exclusion Criteria: * Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)

Outcomes

Primary Outcomes

Withdrawl

Death

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.